ALK-Abelló is a global research-driven pharmaceutical company that focuses on the prevention, diagnosis and treatment of allergies. Before ALK-Abelló partnered with Catalent, all marketed allergen immunotherapies were delivered by injection, resulting in a limited patient population and reduced patient adherence. Catalent worked with the client to apply Zydis® Fast Dissolve Technology to their therapy, bringing a vastly superior product to market. The overall result was a marked improvement in patient tolerability, preference and compliance. This new technology has allowed ALKAbelló to deliver on their promise to improve the quality of life for allergy patients.